Patient Assessments of Skin, Joint, and Nail Disease Activity in Psoriatic Arthritis: Table 1.

Kavanaugh, Arthur; Catalan, Teresa; Cassell, Sarah

doi:10.3899/jrheum.110839

Cited by 6 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand we did not observe a significant correlation with joint disease or with global PsA activity. It is nevertheless noteworthy, as emphasized by Kavanaugh, et al 1 , that some differences may be observed according to the cohort studied.…”

Section: To the Editormentioning

confidence: 94%

“…We thank Dr. Kavanaugh, Dr. Catalan, and Dr. Cassell for their insightful comments and new data on nail involvement and patient's perception of disease in psoriatic arthritis (PsA) 1 . We read with great interest their report, which supports the usefulness of patient self-assessment by means of visual analog scale (VAS) in the evaluation of PsA nail disease.…”

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Dr. Cauli, et al reply: Table 1.

Cauli¹,

Gladman²,

Mathieu³

et al. 2012

J Rheumatol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 94%

Section: To the Editormentioning

confidence: 99%

Dr. Cauli, et al reply: Table 1.

Cauli¹,

Gladman²,

Mathieu³

et al. 2012

J Rheumatol

View full text Add to dashboard Cite

“…Having said that, we do agree with Dr. Kavanaugh that either the NAPSI or mNAPSI could be time consuming to use and rheumatologists may not feel comfortable using them in their daily clinical practice, while the mNAPSI could be good for clinical trials (4) and seems to have good correlation with both physician's and patient's global assessment of psoriatic nail activity (5 …”

Section: To the Editormentioning

confidence: 92%

“…Finally, it is worth noting that the mNAPSI has also been shown to have good correlation with both physician's and patient's global assessment of psoriatic nail activity (Spearman's ϭ 0.93, P Ͻ 0.01 and 0.55, P ϭ 0.01, respectively) (5). Therefore, it may be better for rheumatologists to use the mNAPSI to evaluate the nails of their PsA patients, but if they do not feel comfortable doing so, asking the patients to rate the severity specifically of their nail involvement on a visual analog scale may provide a reasonable approximation.…”

mentioning

confidence: 99%

Reply

Lubrano¹,

Spadaro²

2012

Arthritis Care & Research

View full text Add to dashboard Cite

“…A study by Cozzani and colleagues also demonstrated that PASI and DLQI scores in patients with psoriasis or psoriatic arthritis who were receiving unspecified treatment were correlated, as demonstrated by correlation and linear regression analyses (23). A similar correlation between mNAPSI and DLQI has not been established in patients with psoriasis or psoriatic arthritis; however, mNAPSI has been shown to correlate with the physical component summary score of the Medical Outcomes Study Short Form-36 (27). It has also been established that nail psoriasis can negatively impact QoL (3,28,29).…”

Section: Week 14mentioning

confidence: 98%

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study

Mease

Husni

Chakravarty

et al. 2020

ACR Open Rheumatology

Self Cite

View full text Add to dashboard Cite

Objective. To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis. Methods. Patients were randomized to either IV golimumab 2 mg/kg at weeks 0, 4, then every 8 weeks (q8w) through week 52 or placebo at weeks 0, 4, then q8w, with crossover to IV golimumab 2 mg/kg at weeks 24, 28, and then q8w through week 52. Assessments included Psoriasis Area and Severity Index (PASI), modified Nail Psoriasis Severity Index (mNAPSI), Dermatology Life Quality Index (DLQI), and American College of Rheumatology (ACR) rheumatoid arthritis response criteria. Results. Through week 24, achievement of PASI 75/90/100 responses (P ≤ .0098) and mean improvements in mNAPSI (−11.4 vs −3.7; P < .0001) and DLQI (−9.8 vs −2.9; P < .0001) were significantly greater with golimumab versus placebo. Responses were maintained in patients treated with golimumab through week 52. In placebocrossover patients, increases in the proportion of patients achieving PASI 75/90/100 responses were observed from weeks 24 to 52, and mean improvements in mNAPSI (from −3.7 to −12.9) and DLQI (from −2.9 to −7.8) increased from weeks 24 to 52. Simultaneous achievement of PASI and DLQI responses, PASI and ACR responses, and mNAPSI and DLQI responses were also observed. Similar responses were observed for all assessments regardless of concomitant methotrexate use. Conclusion. Improvements in skin and nail psoriasis symptoms with IV golimumab in patients with psoriatic arthritis were concomitant with improvements in QoL and arthritis disease activity through 1 year. ClinicalTrials.gov identifier: NCT02181673. This work was supported by Janssen Research & Development, LLC. Authors who were employees of the study sponsor participated in the study design and collection, analysis, and interpretation of the data. A medical writer employed by the study sponsor provided writing and editorial support. All authors reviewed and approved the manuscript for submission.

show abstract

Patient Assessments of Skin, Joint, and Nail Disease Activity in Psoriatic Arthritis: Table 1.

Cited by 6 publications

References 3 publications

Dr. Cauli, et al reply: Table 1.

Dr. Cauli, et al reply: Table 1.

Reply

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study

Contact Info

Product

Resources

About